1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protein misfolding and clearance in the pathogenesis of a new infantile onset ataxia caused by mutations in PRDX3

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Peroxiredoxin 3 (PRDX3) encodes a mitochondrial antioxidant protein, which is essential for the control of reactive oxygen species homeostasis. So far, PRDX3 mutations are involved in mild-to-moderate progressive juvenile onset cerebellar ataxia. We aimed to unravel the molecular bases underlying the disease in an infant suffering from cerebellar ataxia that started at 19 months old and presented severe cerebellar atrophy and peripheral neuropathy early in the course of disease. By whole exome sequencing, we identified a novel homozygous mutation, PRDX3 p.D163E, which impaired the mitochondrial ROS defense system. In mouse primary cortical neurons, the exogenous expression of PRDX3 p.D163E was reduced and triggered alterations in neurite morphology and in mitochondria. Mitochondrial computational parameters showed that p.D163E led to serious mitochondrial alterations. In transfected HeLa cells expressing the mutation, mitochondria accumulation was detected by correlative light electron microscopy. Mitochondrial morphology showed severe changes, including extremely damaged outer and inner membranes with a notable cristae disorganization. Moreover, spherical structures compatible with lipid droplets were identified, which can be associated with a generalized response to stress and can be involved in the removal of unfolded proteins. In the patient’s fibroblasts, PRDX3 expression was nearly absent. The biochemical analysis suggested that the mutation p.D163E would result in an unstable structure tending to form aggregates that trigger unfolded protein responses via mitochondria and endoplasmic reticulum. Altogether, our findings broaden the clinical spectrum of the recently described PRDX3-associated neurodegeneration and provide new insight into the pathological mechanisms underlying this new form of cerebellar ataxia.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

          The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants. 1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next generation sequencing. By adopting and leveraging next generation sequencing, clinical laboratories are now performing an ever increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes and epigenetic assays for genetic disorders. By virtue of increased complexity, this paradigm shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context, the ACMG convened a workgroup in 2013 comprised of representatives from the ACMG, the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP and CAP stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories including genotyping, single genes, panels, exomes and genomes. This report recommends the use of specific standard terminology: ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’ to describe variants identified in Mendelian disorders. Moreover, this recommendation describes a process for classification of variants into these five categories based on criteria using typical types of variant evidence (e.g. population data, computational data, functional data, segregation data, etc.). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a CLIA-approved laboratory with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or equivalent.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inference of macromolecular assemblies from crystalline state.

            We discuss basic physical-chemical principles underlying the formation of stable macromolecular complexes, which in many cases are likely to be the biological units performing a certain physiological function. We also consider available theoretical approaches to the calculation of macromolecular affinity and entropy of complexation. The latter is shown to play an important role and make a major effect on complex size and symmetry. We develop a new method, based on chemical thermodynamics, for automatic detection of macromolecular assemblies in the Protein Data Bank (PDB) entries that are the results of X-ray diffraction experiments. As found, biological units may be recovered at 80-90% success rate, which makes X-ray crystallography an important source of experimental data on macromolecular complexes and protein-protein interactions. The method is implemented as a public WWW service.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.

              Byproducts of normal mitochondrial metabolism and homeostasis include the buildup of potentially damaging levels of reactive oxygen species (ROS), Ca(2+), etc., which must be normalized. Evidence suggests that brief mitochondrial permeability transition pore (mPTP) openings play an important physiological role maintaining healthy mitochondria homeostasis. Adaptive and maladaptive responses to redox stress may involve mitochondrial channels such as mPTP and inner membrane anion channel (IMAC). Their activation causes intra- and intermitochondrial redox-environment changes leading to ROS release. This regenerative cycle of mitochondrial ROS formation and release was named ROS-induced ROS release (RIRR). Brief, reversible mPTP opening-associated ROS release apparently constitutes an adaptive housekeeping function by the timely release from mitochondria of accumulated potentially toxic levels of ROS (and Ca(2+)). At higher ROS levels, longer mPTP openings may release a ROS burst leading to destruction of mitochondria, and if propagated from mitochondrion to mitochondrion, of the cell itself. The destructive function of RIRR may serve a physiological role by removal of unwanted cells or damaged mitochondria, or cause the pathological elimination of vital and essential mitochondria and cells. The adaptive release of sufficient ROS into the vicinity of mitochondria may also activate local pools of redox-sensitive enzymes involved in protective signaling pathways that limit ischemic damage to mitochondria and cells in that area. Maladaptive mPTP- or IMAC-related RIRR may also be playing a role in aging. Because the mechanism of mitochondrial RIRR highlights the central role of mitochondria-formed ROS, we discuss all of the known ROS-producing sites (shown in vitro) and their relevance to the mitochondrial ROS production in vivo. Copyright © 2014 the American Physiological Society.
                Bookmark

                Author and article information

                Contributors
                Journal
                Hum Mol Genet
                Hum Mol Genet
                hmg
                Human Molecular Genetics
                Oxford University Press
                0964-6906
                1460-2083
                15 November 2022
                29 June 2022
                29 June 2022
                : 31
                : 22
                : 3897-3913
                Affiliations
                Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Joint Unit CIPF-IIS La Fe Rare Diseases , Valencia 46012, Spain
                Cortical Circuits in Health and Disease Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Cortical Circuits in Health and Disease Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Pediatric Neurology Unit , Department of Pediatrics, Complejo Hospitalario de Navarra , Navarrabiomed, Pamplona 31008, Spain
                Cortical Circuits in Health and Disease Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Structural Enzymopathology Unit, Instituto de Biomedicina de Valencia (IBV), Consejo Superior de Investigaciones Científicas (CSIC), CIBER de Enfermedades Raras (CIBERER-ISCIII) , Valencia 46010, Spain
                Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Electron Microscopy Core Facility, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Service of Advanced Light Microscopy, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Department of Pediatric Neurology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca , Barcelona 08035, Spain
                Cortical Circuits in Health and Disease Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Pediatric Neurology Unit , Department of Pediatrics, Complejo Hospitalario de Navarra , Navarrabiomed, Pamplona 31008, Spain
                Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF) , Valencia 46012, Spain
                Joint Unit CIPF-IIS La Fe Rare Diseases , Valencia 46012, Spain
                Biotechnology Department , Faculty of Veterinary and Experimental Sciences, Universidad Católica de Valencia San Vicente Mártir , Valencia 46001, Spain
                Author notes
                To whom correspondence should be addressed at: Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF), c/Eduardo Primo Yúfera no. 13, 46012 Valencia, Spain. Tel: +34 96 328 9680; Fax: +34 96 328 9701; Email: cespinos@ 123456cipf.es

                Pietro Fazzari, Sergio Aguilera-Albesa and Carmen Espinós last three authors should be regarded as joint last authors.

                Author information
                https://orcid.org/0000-0003-4435-1809
                Article
                ddac146
                10.1093/hmg/ddac146
                9652108
                35766882
                e2297b7e-f7ea-4868-b622-82b8a71d5348
                © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 4 April 2022
                : 9 June 2022
                : 27 June 2022
                : 30 July 2022
                Page count
                Pages: 17
                Funding
                Funded by: European Regional Development Fund, DOI 10.13039/501100008530;
                Award ID: PI18/00147
                Award ID: PI21/00103
                Funded by: Spanish Ministry of Economy and Competitiveness;
                Award ID: SAF2017-89020-R
                Funded by: Fundació la Marató de TV3, DOI 10.13039/100008666;
                Award ID: 20143130
                Award ID: 20143131
                Funded by: Generalitat Valenciana, DOI 10.13039/501100003359;
                Award ID: PROMETEO/2018/135
                Funded by: Spanish Ministry of Science and Innovation, DOI 10.13039/501100004837;
                Award ID: RyC-2014-16410
                Award ID: PRE2018-083562
                Categories
                Original Article
                AcademicSubjects/SCI01140

                Genetics
                Genetics

                Comments

                Comment on this article